Cargando…

Suvorexant: a promising, novel treatment for insomnia

Suvorexant a novel, orexin receptor antagonist was recently approved by the US Food and Drug Administration for the treatment of sleep onset and sleep maintenance insomnia in August 2014. Multiple animal and human studies support the efficacy, safety, and tolerability of suvorexant for patients of v...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee-Iannotti, Joyce K, Parish, James M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4772996/
https://www.ncbi.nlm.nih.gov/pubmed/26955275
http://dx.doi.org/10.2147/NDT.S31495

Ejemplares similares